The impact of the COVID-19 pandemic on rates of adolescents receiving psychopharmacological medication in Austria

Author:

Otter M.,Kothgassner O. D.,Lepuschütz L.,Drahos S.,Plener P. L.

Abstract

Abstract Background The COVID-19 pandemic has impacted many aspects of everyday life, including the (mental) healthcare system. An increase in depression and anxiety symptoms has been reported worldwide, and is particularly pronounced in females and young people. We aimed to evaluate changes in prescription rates for psychopharmacological medication, which is often used to treat depression and anxiety. Method Based on data from the Austrian public health insurance institutions, we conducted an interrupted time series analysis of antidepressants and antipsychotics, comparing prescription rate developments before and throughout the COVID-19 pandemic (2013 to 2021), with a special focus on adolescents (10–19 years) in comparison to the general population. Data were based on all public prescriptions in the outpatient sector nationwide. Age- and sex-stratified time-series models were fitted to the pre-COVID period (first quarter (Q1) of 2013 to second quarter (Q2) of 2020). These were used to generate forecasts for the period from the third quarter (Q3) of 2020 to the fourth quarter (Q4) of 2021, which were subsequently compared to observed developments in order to assess significant deviations from the forecasted development paths. Results For the majority of the evaluated period, we found a significant excess of antidepressant prescriptions among both male and female adolescents (10–14 and 15–19 years) compared to the forecasted development path, while the general population was mostly within 97.5% confidence intervals of the forecasts. Regarding antipsychotics, the interrupted time series analysis revealed a significant excess in the group of female adolescents in almost all quarters, which was especially pronounced in the 15–19 age group. Prescription rates of antipsychotics in the general population only showed a significant excess in two quarters. Conclusion Increased rates of adolescents receiving psychopharmacological treatment echo the epidemiological trends of an increase in depression and anxiety symptoms reported in the literature. This increase is especially pronounced in female adolescents.

Publisher

Springer Science and Business Media LLC

Reference43 articles.

1. American Academy of child and adolescent psychiatry. anxiety disorders: parents´ medication guide. 2020. https://www.aacap.org/App_Themes/AACAP/docs/resource_centers/resources/med_guides/anxiety-parents-medication-guide.pdf. Accessed 20 Nov 2022.

2. Amill-Rosario A, Lee H, Zhang C, dosReis S. Psychotropic prescriptions during the COVID-19 pandemic among us children and adolescents receiving mental health services. J Child Adolesc Psychopharmacol. 2022;32(7):408–14. https://doi.org/10.1089/cap.2022.0037.

3. Bliddal M, Rasmussen L, Andersen JH, Jensen PB, Pottegård A, Munk-Olsen T, Kildegaard H, Wesselhoeft R. Psychotropic medication use and psychiatric disorders during the COVID-19 pandemic among Danish children, adolescents, and young adults. JAMA Psychiat. 2023;80(2):176–80. https://doi.org/10.1001/jamapsychiatry.2022.4165.

4. Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, Rubin GJ. The psychological impact of quarantine and how to reduce it: a rapid review of the evidence. Lancet. 2020;395(10227):912–20. https://doi.org/10.1016/S0140-6736(20)30460-8.

5. Bruns N, Willemsen L, Stang A, Kowall B, Holtkamp K, Kamp O, Dudda M, Hey F, Hoffmann F, Blankenburg J, Eifinger F, Fuchs H, Haase R, Baier J, Andrée C, Heldmann M, Maldera V, Potratz J, Kurz D, Mand N, Doerfel C, Rothoeft T, Schultz M, Ohlert M, Silkenbäumer K, Boesing T, Indraswari F, Niemann F, Jahn P, Merker M, Braun N, Nunez FB, Engler M, Heimann K, Brasche M, Wolf G, Freymann H, Dercks M, Hoppenz M, Felderhoff-Müser U, Dohna-Schwake C. Pediatric ICU admissions after adolescent suicide attempts during the pandemic. Pediatrics. 2022;150(2): e2021055973. https://doi.org/10.1542/peds.2021-055973.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3